Related Experiment Video
Updated: Jun 22, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
[Biotherapies and Parkinson's disease]
1Clinique neurologique, département de neurosciences cliniques, CHU Henri-Mondor, 51, avenue du Maréchal-De-Lattre-de-Tassigny, 94000 Créteil, France. pierre.cesaro@hmn.aphp.fr
Revue Neurologique
|June 3, 2009
Summary
Experimental biotherapies for Parkinson's disease are evolving. While fetal cell transplants and retinal cell therapies faced challenges, stem cells and gene therapy show promise for future Parkinson's disease treatments.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Biotherapy
Context:
- Parkinson's disease (PD) treatment research has explored various biotherapies.
- Fetal dopaminergic transplants showed early promise but faced limitations and trial failures.
- Recent approaches using retinal pigmented cells yielded disappointing clinical results.
Purpose:
- To review the progress and challenges of experimental biotherapies for Parkinson's disease.
- To evaluate the efficacy and limitations of different cell-based and gene therapy strategies.
- To highlight emerging therapeutic avenues for Parkinson's disease.
Summary:
- Fetal dopaminergic cell transplantation, while conceptually sound, encountered significant hurdles in clinical trials.
- Alternative cell sources, including retinal pigmented cells, have not yet proven effective for Parkinson's disease.
- Stem cell-derived dopaminergic neurons and gene therapy represent promising, albeit still experimental, future directions for Parkinson's disease treatment.
Impact:
- The evolution of Parkinson's disease biotherapies highlights the need for innovative and effective treatments.
- Understanding the limitations of past approaches informs the development of next-generation Parkinson's disease therapies.
- Gene therapy and stem cell research offer potential breakthroughs in managing Parkinson's disease symptoms and progression.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.